Menu
Innovation Observatory > Reports > Cancer and Palliative Care

Results

Drugs

December 2017

Nab-paclitaxel in Combination with Gemcitabine for Resected Pancreatic Ductal Adenocarcinoma – Adjuvant Therapy

Paclitaxel formulated as albumin bound nanoparticles (Nab-paclitaxel) in combination with gemcitabine is being developed as a treatment option for patients with pancreatic cancer who have undergone surgery to increase the chances of being cured (‘adjuvant therapy’). Both drugs are chemotherapies already being used to treat metastatic pancreatic cancer and other types of cancers and are administered by injection.

Drugs

December 2017

Blinatumomab (Blincyto) for First Relapsed/Refractory, B-precursor, Acute Lymphoblastic Leukaemia, in Children and Adolescents

Blinatumomab is a type of drug called a monoclonal antibody. Monoclonal antibodies work by seeking out cancer cells by looking for particular proteins on the cells’ surface. Blinatumomab is a new drug that is already used to treat ALL in adults and is currently being studied to see how well it works and whether it is safe to use in children and young people with ALL.

Drugs

December 2017

Lenalidomide (Revlimid) for Newly Diagnosed Multiple Myeloma – First Line

Lenalidomide in combination with bortezomib and dexamethasone is being developed for the treatment of adult patients with MM. While each of these drugs are already approved for treating a range of malignant blood diseases, the combination of the three drugs has shown significant potential particularly for the treatment of newly diagnosed MM. If approved, it …

Drugs

December 2017

IMCgp100 for the Treatment of Advanced or Metastatic Uveal Melanoma

There are currently few effective treatments available for advanced or metastatic uveal melanoma, including surgery to remove the cancer, radiotherapy or chemotherapy. IMCgp100 is a drug under development that would enable the body’s own immune system to recognise and specifically target and kill cancer cells.

Drugs

December 2017

Ribociclib and Fulvestrant and PI3K Inhibitor (Buparlisib or Alpelisib) for HR Positive, HER2 Negative Postmenopausal Breast Cancer – Second or Third Line

The combination of ribociclib, fulvestrant, and buparlisib or alpelisib is being developed for the treatment of HR+ and HER2- locally recurrent or advanced metastatic breast cancer. Ribociclib is given by mouth (capsules). It acts by helping to slow the progression of cancer by inhibiting two certain types of proteins that play a role in ensuring …

Drugs

December 2017

Venetoclax in Combination with Obinutuzumab for the Treatment of Previously Untreated Chronic Lymphocytic Leukaemia – First Line

Venetoclax is a drug that attaches to a protein in the body called Bcl-2. This protein presents in high amounts in CLL cancer cells, where it helps the cancer cells survive for longer in the body and makes them resistant to cancer medicines. Venetoclax causes the death of cancer cells and thereby slows the progression …

Drugs

December 2017

Veliparib in Combination with Carboplatin and Paclitaxel for Breast Cancer – First to Third Line

Veliparib is a new oral drug that is being developed for patients with HER2- breast cancer that is advanced and cannot be removed completely through surgery. The drug acts by targeting specific enzymes involved in the repair of damaged DNA that helps the body to kill cancer cells while allowing ordinary cells to survive.

Drugs

December 2017

Taselisib in Combination with Fulvestrant for Advanced ER Positive, HER2-negative Breast Cancer – Second Line After Aromatase Inhibitor Therapy

Taselisib is investigated as a new oral treatment for ER+, HER2- type of breast cancer. It is being investigated as a medicine to work on a pathway regulating cell growth and cell survival. If taken in combination with an intramuscular injection of fulvestrant, which stops the effect of hormones altering the breast cells, taselisib has the potential to prolong survival.

Drugs

December 2017

Alpelisib in Combination with Fulvestrant for Advanced HR Positive, HER2-negative Breast Cancer in Men and Postmenopausal Women

Alpelisib is a new drug that is being developed for patients with the HR+/HER2- type of advanced breast cancer. Alpelisib targets a very specific enzyme that transmits signals to cells, stopping the growth and survival of cancer cells.

Drugs

December 2017

Guadecitabine for Treatment of Naïve Acute Myeloid Leukaemia

Guadecitabine is a new treatment being developed for patients who have not received prior treatment (treatment naïve) and are ineligible to undergo intensive chemotherapy.

Get Alerts